Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2009 | Original Article

Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT

Authors: Kazuhiro Kitajima, Koji Murakami, Erena Yamasaki, Yasushi Domeki, Masahiro Tsubaki, Masakatsu Sunagawa, Yasushi Kaji, Narufumi Suganuma, Kazuro Sugimura

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2009

Abstract

Purpose

The aim of our study was to evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using ¹⁸F-fluorodeoxyglucose (FDG) with IV contrast for depiction of suspected recurrent colorectal cancer and to assess the impact of PET/contrast-enhanced CT findings on clinical management compared with PET/non-contrast-enhanced CT and CT component.

Methods

One hundred seventy patients previously treated for colorectal cancer underwent PET/CT consisting of non-enhanced and contrast-enhanced CT for suspected recurrence. PET/contrast-enhanced CT, PET/non-contrast-enhanced CT and enhanced CT were interpreted by two experienced radiologists by consensus for each investigation. Lesion status was determined on the basis of histopathology, radiological imaging and clinical follow-up for longer than 6 months.

Results

Patient-based analysis showed that the sensitivity, specificity and accuracy of PET/contrast-enhanced CT were 93.2 (69/74), 95.8 (92/96) and 94.7% (161/170), respectively, whereas those of PET/non-contrast-enhanced CT were 89.2 (66/74), 94.8 (91/96) and 92.4% (157/170), respectively, and those of enhanced CT were 79.7 (59/74), 93.8 (90/96) and 87.6% (149/170), respectively. Sensitivity and accuracy differed significantly among the three modalities (Cochran’s Q test: p = 0.0004 and p = 0.0001, respectively).The findings of PET/contrast-enhanced CT resulted in a change of management for 64 of the 170 patients (38%) and had an effect on patient management in 12 patients (7%) diagnosed by enhanced CT alone and 4 patients (2%) diagnosed by PET/non-contrast-enhanced CT.

Conclusion

Integrated PET/contrast-enhanced CT is an accurate modality for assessing colorectal cancer recurrence and led to changes in the subsequent appropriate therapy.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.PubMedCrossRef

Arriola E, Navarro M, Pares D, Munoz M, Pareja L, Figueras J, et al. Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer. Dis Colon Rectum 2006;49:478–84. doi:10.1007/s10350-005-0280-9.PubMedCrossRef

Abir F, Alva S, Longo WE, Audiso R, Virgo KS, Johnson FE, et al. The postoperative surveillance of patients with colon cancer and rectal cancer. Am J Surg 2006;192:100–8. doi:10.1016/j.amjsurg.2006.01.053.PubMedCrossRef

Fernandes LC, Kim SB, Saad SS, Matos D. Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer. World J Gastroenterol 2006;12:3891–4.PubMed

Engstorm PF. NCCN clinical practice guidelines in oncology: colon cancer. National Comprehensive Cancer Network; 2007:2. Available at http://www.nccn.org. Accessed 28 Jan 2008.

Stueckle CA, Adams S, Stueckle KF, Szpakowski M, Schneider O, Friedrich C, et al. Multi-detector CT in the evaluation of patients with recurrence of rectal cancer. Technol Cancer Res Treat 2006;5:285–9.PubMed

Titu LV, Nicholson AA, Hartley JE, Breen DJ, Monson JR. Routine follow-up by magnetic resonance imaging does not improve detection of resectable local recurrences from colorectal cancer. Ann Surg 2006;243:348–52. doi:10.1097/01.sla.0000201454.20253.07.PubMedCrossRef

Torricelli P, Pecchi A, Luppi G, Romagnoli R. Gadolinium-enhanced MRI with dynamic evaluation in diagnosing the local recurrence of rectal cancer. Abdom Imaging 2003;28:19–27. doi:10.1007/s00261-001-0127-3.PubMedCrossRef

Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200–9.PubMed

10.

Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of ¹⁸F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44:1797–803.PubMed

11.

Kim JH, Crernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, et al. Comparison between ¹⁸F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005;46:587–95.PubMed

12.

Kamel IR, Cohade C, Neyman E, Fishman EK, Wahl RL. Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdom Imaging 2004;29:663–8. doi:10.1007/s00261-003-0163-2.PubMedCrossRef

13.

Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004;232:815–22. doi:10.1148/radiol.2323031065.PubMedCrossRef

14.

Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2006;33:779–84. doi:10.1007/s00259-006-0072-z.PubMedCrossRef

15.

Chen LB, Tong JL, Song HZ, Zhu H, Wang YC. ¹⁸F-FDG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 2007;13:5025–9.PubMed

16.

Soyka JD, Veit-Haibach P, Strobel K, Breitenstein S, Tschopp A, Mende KA, et al. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced ¹⁸F-FDG PET/CT the diagnostic tool of choice. J Nucl Med 2008;49:354–61. doi:10.2967/jnumed.107.048249.PubMedCrossRef

17.

Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003;229:526–33. doi:10.1148/radiol.2292021598.PubMedCrossRef

18.

Antoch G, Saoudi N, Kuehl H, Dahmen G, Muller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004;22:4357–68. doi:10.1200/JCO.2004.08.120.PubMedCrossRef

19.

Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Fukasawa I, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging 2008;35:1439–48. doi:10.1007/s00259-008-0776-3.PubMedCrossRef

20.

Bristow RE, Giuntoli RL 2nd, Pannu HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005;99:294–300. doi:10.1016/j.ygyno.2005.06.019.PubMedCrossRef

21.

Kitajima K, Murakami K, Yamasaki E, Fukasawa I, Inaba N, Kaji Y, et al. Accuracy of FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am J Roentgenol 2008;190:1652–8. doi:10.2214/AJR.07.3372.PubMedCrossRef

22.

Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging 2004;39:398–403.

23.

Bipat S, van Leeuwen MS, Comans EFI, Piji ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis. Radiology 2005;237:123–31.PubMedCrossRef

24.

Ward J. New MR techniques for the detection of liver metastases. Cancer Imaging 2006;6:33–42. doi:10.1102/1470-7330.2006.0007.PubMedCrossRef

25.

Squillaci E, Manenti G, Mancino S, Ciccio C, Calabria F, Donieli R, et al. Staging of colon cancer: whole-body MRI vs. whole body PET/CT—initial clinical experience. Abdom Imaging 2008;33:676–88. doi:10.1007/s00261-007-9347-5.PubMedCrossRef

26.

Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, et al. Diagnostic efficacy of gadoxetic acid (primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008;18:457–67. doi:10.1007/s00330-007-0716-9.PubMedCrossRef

27.

Coleman ER, Delbeke D, Guiberteau MJ, Conti PS, Royal HD, Weinreb JC, et al. Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med 2005;46:1225–39.PubMed

28.

Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography—clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med 2003;33:228–37. doi:10.1053/snuc.2003.127312.PubMedCrossRef

29.

Schaefer NG, Hany TF, Taverna C, Taverna C, Seifert B, Stumpe KD, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology 2004;232:823–9. doi:10.1148/radiol.2323030985.PubMedCrossRef

30.

Rodríguez-Vigil B, Gómez-León N, Pinilla I, Hernández-Maraver D, Coya J, Martín-Curto L, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 2006;47:1643–8.PubMed

31.

Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? ¹⁸F-FDG and CT contrast agents in dual-modality ¹⁸F-FDG PET/CT. J Nucl Med 2004;45:56–65.

32.

Mawlawi O, Erasmus JJ, Munden RF, Pan T, Knight A, Macapinlac HA, et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol 2006;186:308–19. doi:10.2214/AJR.04.1740.PubMedCrossRef

33.

Pfannenberg AC, Aschoff P, Brechtel K, Müller M, Bares R, Paulsen F, et al. Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:36–44. doi:10.1007/s00259-006-0186-3.PubMedCrossRef

34.

Pfannenberg AC, Aschoff P, Brechtel K, Müller M, Klein M, Bares R, et al. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol 2007;80:437–45. doi:10.1259/bjr/34082277.PubMedCrossRef

Title: Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT
Authors: Kazuhiro Kitajima
Koji Murakami
Erena Yamasaki
Yasushi Domeki
Masahiro Tsubaki
Masakatsu Sunagawa
Yasushi Kaji
Narufumi Suganuma
Kazuro Sugimura
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1081-5

At a glance: The STEP trials

Springer Medicine

Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2009

68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging

Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients

EANM guidelines for ventilation/perfusion scintigraphy

Eugene C. Lin, Edward J. Escott, Kavita D. Garg, Andrew G. Bleicher, David Alexander: Practical differential diagnosis for CT and MRI

The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy

Incidental head and neck 18F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development?